Trevena
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.
Launch date
Employees
Market cap
€4.6m
Enterprise valuation
€23m (Public information from Sep 2024)
Share price
$4.7 TRVN
Upper Merion Township Pennsylvania (HQ)
Authorizing premium user...